Related Experiment Video
Updated: Aug 15, 2026
Improved Rodent Model of Myocardial Ischemia and Reperfusion Injury
Published on: March 7, 2022
Oleylethanolamide activates Ras-Erk pathway and improves myocardial function in doxorubicin-induced heart failure
Hou-Fen Su1, Ahmad Samsamshariat, Jin Fu
1Department of Medicine, University of California, Irvine, 92697, USA.
Abstract:
Oleylethanolamide (OEA) is a natural fatty acid ethanolamide produced in the heart, but its biological actions in myocardium have not yet been defined. This study was carried out to determine whether OEA could be used to prevent the development of heart failure or improve evolving heart failure. We studied in vivo and in vitro actions of OEA in cardiac muscle. In an animal model of doxorubicin cardiomyopathy, OEA showed robust effects and attenuated the progression of systolic/diastolic dysfunction and ventricular remodeling. During evolving doxorubicin cardiomyopathy, a therapeutic course of OEA treatment partially restored myocardial function. The preventive and therapeutic effects of OEA were associated with significant improvement of survival. To investigate the mechanism of OEA action in cardiac muscle, we have carried out in vitro experiments in cultured cardiomyocytes. The results showed that OEA, through activation of Ras-Raf-1-Mek-Erk signaling, inhibited doxorubicin-induced apoptosis. Additional experiments showed that OEA activation of the Erk pathway involved activation of Neu/ErbB2 receptor, which suggests OEA actions in cardiac muscle might require activation of Neu/ErbB2. In summary, OEA improved ventricular remodeling and augmented cardiac function in doxorubicin cardiomyopathy, possibly involving activation of Neu/ErbB2 and Ras-Erk signaling. These findings suggest OEA is a novel cardioprotective compound that may be used to develop new strategies for the management of cardiomyopathy.
Insights
Oleylethanolamide (OEA) may prevent and treat heart failure by protecting cardiac muscle cells. This natural compound improved survival and cardiac function in animal models, suggesting potential for new heart disease therapies.
Area of Science:
- Cardiology
- Molecular Biology
- Pharmacology
Background:
- Oleylethanolamide (OEA) is a naturally occurring fatty acid ethanolamide found in the heart.
- The specific biological functions of OEA within the myocardium remain largely undefined.
- Understanding OEA's role is crucial for developing novel therapeutic strategies for heart conditions.
Purpose of the Study:
- To investigate the potential of Oleylethanolamide (OEA) in preventing and treating heart failure.
- To elucidate the underlying molecular mechanisms of OEA's action in cardiac muscle.
- To assess OEA's efficacy in an animal model of doxorubicin-induced cardiomyopathy.
Main Methods:
- In vivo studies utilizing an animal model of doxorubicin cardiomyopathy.
- In vitro experiments with cultured cardiomyocytes to examine cellular mechanisms.
- Analysis of signaling pathways, including Ras-Raf-1-Mek-Erk and Neu/ErbB2 receptor activation.
Main Results:
- Oleylethanolamide (OEA) demonstrated significant cardioprotective effects, attenuating systolic/diastolic dysfunction and ventricular remodeling in doxorubicin cardiomyopathy.
- OEA treatment partially restored myocardial function and improved survival rates in affected animals.
- In vitro, OEA inhibited doxorubicin-induced apoptosis by activating the Ras-Erk signaling pathway, potentially via Neu/ErbB2 receptor engagement.
Conclusions:
- Oleylethanolamide (OEA) exhibits novel cardioprotective properties, improving cardiac function and ventricular remodeling in a model of cardiomyopathy.
- The cardioprotective effects of OEA appear to involve the activation of Neu/ErbB2 and Ras-Erk signaling pathways.
- OEA represents a promising therapeutic candidate for developing new strategies in the management of heart failure and related conditions.
Related Concept Videos
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
01:26Heart Failure Drugs: Inotropic Agents